SION - Sionna Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$27.20
DETAILS
HIGH:
$60.00
LOW:
$5.00
MEDIAN:
$7.00
CONSENSUS:
$27.20
UPSIDE:
414.18%
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0.6 | 0.7 | 0 | 0 |
| Gross Profit | (0.6) | (0.7) | 0 | 0 |
| Operating Expenses | ||||
| R&D Expenses | 60.3 | 57.3 | 40.6 | 34.6 |
| SG&A Expenses | 28.7 | 13.3 | 9.7 | 6.8 |
| Other Expenses | (0.6) | (0.7) | 0 | 0 |
| Operating Expenses | 88.3 | 69.9 | 50.3 | 41.4 |
| Operating Income | ||||
| Operating Income | (89.0) | (70.6) | (50.3) | (41.4) |
| Interest Expense | 0 | 0 | 0 | 0 |
| Interest Income | 13.3 | 8.2 | 2.8 | 1.1 |
| Profitability | ||||
| EBITDA | (74.6) | (61.0) | (46.7) | (40.1) |
| EBIT | (75.3) | (61.7) | (47.3) | (40.2) |
| Income Before Tax | (75.3) | (61.7) | (47.3) | (40.2) |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (75.3) | (61.7) | (47.3) | (40.2) |
| Per Share Data | ||||
| EPS (Basic) | -1.88 | -1.40 | -1.07 | -0.91 |
| EPS (Diluted) | -1.88 | -1.40 | -1.07 | -0.91 |
| Shares Outstanding | 40.0 | 44.1 | 44.1 | 44.1 |
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Current Assets | ||||
| Cash & Cash Equivalents | 58.5 | 37.8 | 38.5 | 54.8 |
| Short-Term Investments | 177.4 | 109.8 | 0 | 27.8 |
| Net Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Other Current Assets | 5.5 | 3.5 | 0.7 | 1.2 |
| Total Current Assets | 241.4 | 151.0 | 39.2 | 83.8 |
| Non-Current Assets | ||||
| Property, Plant & Equipment | 9.2 | 10.3 | 11.7 | 2.6 |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 74.4 | 20.5 | 1.0 | 0 |
| Other Non-Current Assets | 1.0 | 4.0 | 0.0 | 1.0 |
| Total Non-Current Assets | 84.5 | 34.8 | 12.7 | 3.5 |
| Total Assets | 326.0 | 185.8 | 51.9 | 87.4 |
| Current Liabilities | ||||
| Account Payables | 0.8 | 1.2 | 0.7 | 0.6 |
| Short-Term Debt | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.7 | 3.0 | 3.1 | 2.0 |
| Total Current Liabilities | 11.7 | 10.4 | 8.0 | 8.3 |
| Non-Current Liabilities | ||||
| Long-Term Debt | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 330.4 | 149.0 | 149.0 |
| Total Non-Current Liabilities | 7.4 | 339.0 | 158.8 | 149.0 |
| Total Liabilities | 19.1 | 349.5 | 166.8 | 157.3 |
| Stockholders' Equity | ||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 |
| Retained Earnings | (256.4) | (181.1) | (119.4) | (72.1) |
| Accumulated Other Comprehensive Income | 0.5 | 0.4 | 0 | (0.0) |
| Total Stockholders' Equity | 306.8 | (163.7) | (114.9) | (69.9) |
| Total Liabilities & Equity | 326.0 | 185.8 | 51.9 | 87.4 |
| Debt Metrics | ||||
| Total Debt | 8.7 | 9.7 | 10.5 | 0 |
| Net Debt | (49.8) | (28.0) | (28.0) | (54.8) |
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | (75.3) | (61.7) | (47.3) | (40.2) |
| Depreciation & Amortization | (3.1) | 0.7 | 0.6 | 0.1 |
| Stock-Based Compensation | 12.1 | 3.7 | 2.3 | 1.7 |
| Change in Working Capital | (2.7) | (3.1) | (0.8) | 2.8 |
| Other Non-Cash Items | 2.6 | 7.6 | 1.5 | (0.4) |
| Operating Cash Flow | (66.3) | (52.8) | (43.7) | (36.1) |
| Investing Activities | ||||
| Capital Expenditure | (0.4) | (0.0) | (1.1) | (1.9) |
| Acquisitions | 0 | 0 | 0 | 0 |
| Purchases of Investments | (325.0) | (182.8) | (23.5) | (40.4) |
| Sales/Maturities of Investments | 206.7 | 56.0 | 52 | 13 |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (118.7) | (126.9) | 27.4 | (29.3) |
| Financing Activities | ||||
| Net Debt Issuance | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0.1 |
| Financing Cash Flow | 205.7 | 179.0 | 0.0 | 110.9 |
| Cash Position | ||||
| Net Change in Cash | 20.7 | (0.7) | (16.3) | 45.5 |
| Cash at Beginning | 38.8 | 39.5 | 55.8 | 10.3 |
| Cash at End | 59.4 | 38.8 | 39.5 | 55.8 |
| Free Cash Flow | (66.7) | (52.8) | (44.8) | (37.9) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | (0.6) | (0.7) | 0 | 0 |
| Operating Income | (89.0) | (70.6) | (50.3) | (41.4) |
| Net Income | (75.3) | (61.7) | (47.3) | (40.2) |
| EPS (Diluted) | -1.88 | -1.40 | -1.07 | -0.91 |
| Balance Sheet | ||||
| Cash & Equivalents | 58.5 | 37.8 | 38.5 | 54.8 |
| Total Assets | 326.0 | 185.8 | 51.9 | 87.4 |
| Total Debt | 8.7 | 9.7 | 10.5 | 0 |
| Stockholders' Equity | 306.8 | (163.7) | (114.9) | (69.9) |
| Cash Flow | ||||
| Operating Cash Flow | (66.3) | (52.8) | (43.7) | (36.1) |
| Capital Expenditure | (0.4) | (0.0) | (1.1) | (1.9) |
| Free Cash Flow | (66.7) | (52.8) | (44.8) | (37.9) |